Search results for " tumor"

showing 10 items of 3819 documents

Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial

2020

[Background] Solitary fibrous tumour is an ultra-rare sarcoma, which encompasses different clinicopathological subgroups. The dedifferentiated subgroup shows an aggressive course with resistance to pazopanib, whereas in the malignant subgroup, pazopanib shows higher activity than in previous studies with chemotherapy. We designed a trial to test pazopanib activity in two different cohorts of solitary fibrous tumour: the malignant-dedifferentiated cohort, which was previously published, and the typical cohort, which is presented here.

0301 basic medicineMalemedicine.medical_specialtyIndazolesPazopanib03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointHumansProspective StudiesNeoplasm MetastasisProspective cohort studySurvival rateProtein Kinase InhibitorsResponse Evaluation Criteria in Solid TumorsAgedSulfonamidesPerformance statusbusiness.industryMiddle Agedmedicine.diseasePrognosisClinical trialSurvival Rate030104 developmental biologyPyrimidinesOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisSolitary Fibrous TumorsFemalebusinessProgressive diseasemedicine.drugFollow-Up Studies
researchProduct

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-…

2019

Abstract Background Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions Our findings support in clinical practice …

0301 basic medicineMalemedicine.medical_specialtyMeta-AnalysiBone Density Conservation Agentmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsBone NeoplasmZoledronic Acidlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansHypocalcaemiaBreastAdverse effectBone Density Conservation AgentsSolid tumorbusiness.industryMortality rateProstateProstatic NeoplasmsAEHematologyBisphosphonateSMRmedicine.diseaseBone metastase030104 developmental biologyZoledronic acidTreatment OutcomeOncology030220 oncology & carcinogenesisMeta-analysisProstatic NeoplasmFemalebusinessBreast Neoplasmmedicine.drugHuman
researchProduct

Fabrication of amorphous strontium polyphosphate microparticles that induce mineralization of bone cells in vitro and in vivo.

2017

Abstract Here we describe the fabrication process of amorphous strontium-polyphosphate microparticles (“Sr-a-polyP-MP”). The effects of these particles on growth and gene expression were investigated with SaOS-2 cells as well as with human mesenchymal stem cells (MSC) and compared with those particles prepared of amorphous calcium-polyphosphate (“Ca-a-polyP-MP”) and of strontium salt. The results revealed a markedly higher stimulation of growth of MSC by “Sr-a-polyP-MP” compared to “Ca-a-polyP-MP” and a significant increase in mineralization of SaOS-2 cells, as well as an enhanced upregulation of the expression of the genes encoding for alkaline phosphatase and the bone morphogenetic protei…

0301 basic medicineMaterials scienceBiomedical Engineering02 engineering and technologyBone healingBiochemistryBone morphogenetic protein 2OsteocytesBiomaterials03 medical and health scienceschemistry.chemical_compoundCalcification PhysiologicIn vivoPolyphosphatesCell Line TumorBone cellAnimalsHumansMolecular BiologyWnt Signaling PathwayBone mineralMesenchymal Stem CellsGeneral Medicine021001 nanoscience & nanotechnologyAntigens Differentiationdigestive system diseasesMicrospheresCell biologyRatsPLGA030104 developmental biologychemistryGene Expression RegulationStrontiumSclerostinAlkaline phosphatase0210 nano-technologyBiotechnologyBiomedical engineeringActa biomaterialia
researchProduct

EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumors

2018

Abstract Glioblastoma (GBM) is a typically lethal type of brain tumor with a median survival of 15 months postdiagnosis. This negative prognosis prompted the exploration of alternative treatment options. In particular, the reliance of GBM on angiogenesis triggered the development of anti‐VEGF (vascular endothelial growth factor) blocking antibodies such as bevacizumab. Although its application in human GBM only increased progression‐free periods but did not improve overall survival, physicians and researchers still utilize this treatment option due to the lack of adequate alternatives. In an attempt to improve the efficacy of anti‐VEGF treatment, we explored the role of the egfl7 gene in ma…

0301 basic medicineMedicine (General)Vascular Biology & AngiogenesisAngiogenesisEndothelial Growth FactorsQH426-470chemistry.chemical_compoundangiogenesisMice0302 clinical medicineAntineoplastic Agents ImmunologicalResearch ArticlesCancerNeovascularization PathologicBrain NeoplasmsEndothelial stem cellVascular endothelial growth factormedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisendothelial cellMolecular MedicineHeterograftsEGFL7PericyteEGFL7medicine.drugResearch ArticleIntegrin alpha5beta1EGF Family of ProteinsintegrinBrain tumor03 medical and health sciencesR5-920GliomamedicineGeneticsHuman Umbilical Vein Endothelial CellsAnimalsHumansddc:610Cell ProliferationTemozolomidebusiness.industryCalcium-Binding ProteinsglioblastomaEndothelial Cellsmedicine.diseaseSurvival AnalysisDisease Models Animal030104 developmental biologychemistryCancer researchbusinessNeoplasm TransplantationNeuroscienceEMBO Molecular Medicine
researchProduct

Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous Leukemia cell growth

2017

Despite Imatinib (IM), a selective inhibitor of Bcr-Abl, having led to improved prognosis in Chronic Myeloid Leukemia (CML) patients, acquired resistance and long-term adverse effects is still being encountered. There is, therefore, urgent need to develop alternative strategies to overcome drug resistance. According to the molecules expressed on their surface, exosomes can target specific cells. Exosomes can also be loaded with a variety of molecules, thereby acting as a vehicle for the delivery of therapeutic agents. In this study, we engineered HEK293T cells to express the exosomal protein Lamp2b, fused to a fragment of Interleukin 3 (IL3). The IL3 receptor (IL3-R) is overexpressed in CML…

0301 basic medicineMedicine (miscellaneous)PharmacologyEngineered exosomeExosomesInterleukin 3Antineoplastic AgentMiceHEK293 Cellhemic and lymphatic diseasesDrug CarrierPharmacology Toxicology and Pharmaceutics (miscellaneous)Drug CarriersChronic myeloid leukemiaMyeloid leukemiaChronic myeloid leukemia; Drug delivery; Drug resistance; Engineered exosomes; Interleukin 3; Animals; Antineoplastic Agents; Cell Line Tumor; Cell Proliferation; Disease Models Animal; Drug Carriers; Exosomes; HEK293 Cells; Heterografts; Humans; Imatinib Mesylate; Leukemia Myelogenous Chronic BCR-ABL Positive; Mice; Receptors Interleukin-3; Treatment Outcome3. Good healthTreatment OutcomeImatinib MesylateHeterograftsHeterograftResearch Papermedicine.drugHumanEngineered exosomesAntineoplastic Agents03 medical and health sciencesIn vivoCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineAnimalsHumansneoplasmsInterleukin 3.Interleukin 3Cell Proliferationbusiness.industryAnimalImatinibmedicine.diseaseMicrovesiclesReceptors Interleukin-3ExosomeDisease Models AnimalHEK293 Cells030104 developmental biologyImatinib mesylateDrug resistanceCancer cellDrug deliverybusinessChronic myelogenous leukemia
researchProduct

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

2016

Abstract Purpose: The onset of drug resistance is a major cause of treatment failure in multiple myeloma. Although increasing evidence is defining the role of miRNAs in mediating drug resistance, their potential activity as drug-sensitizing agents has not yet been investigated in multiple myeloma. Experimental Design: Here we studied the potential utility of miR-221/222 inhibition in sensitizing refractory multiple myeloma cells to melphalan. Results: miR-221/222 expression inversely correlated with melphalan sensitivity of multiple myeloma cells. Inhibition of miR-221/222 overcame melphalan resistance and triggered apoptosis of multiple myeloma cells in vitro, in the presence or absence of…

0301 basic medicineMelphalanCancer ResearchStromal cellApoptosisDrug resistancePharmacologyArticle03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicinemyeloma microRNA mir-221 melphalanimmune system diseasesIn vivohemic and lymphatic diseasesCell Line TumorProto-Oncogene ProteinsmedicineAnimalsHumansMelphalanMultiple myelomaNOD miceCell Proliferationbusiness.industryCancermedicine.diseaseXenograft Model Antitumor AssaysGene Expression Regulation NeoplasticMicroRNAs030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisGrowth inhibitionMultidrug Resistance-Associated ProteinsbusinessApoptosis Regulatory ProteinsMultiple Myelomamedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Proton-coupled folate transporter as a biomarker of outcome to treatment for pleural mesothelioma.

2018

0301 basic medicineMesotheliomaLung NeoplasmsPleural NeoplasmsPemetrexed03 medical and health sciences0302 clinical medicineGeneticsmedicineBiomarkers TumorHumansMesotheliomaProton-coupled folate transporterPharmacologybusiness.industryPleural mesotheliomaMesothelioma Malignantmedicine.diseasechemoresistance mesothelioma PCFT pemetrexed030104 developmental biologyPemetrexedDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchMolecular MedicineBiomarker (medicine)businessProton-Coupled Folate Transportermedicine.drugPharmacogenomics
researchProduct

Insulin Resistance in PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase

2016

Cardiovascular diseases and oxidative stress are related to polycystic ovary syndrome (PCOS) and insulin resistance (IR). We have evaluated the relationship between myeloperoxidase (MPO) and leukocyte activation in PCOS patients according to homeostatic model assessment of IR (HOMA-IR), and have explored a possible correlation between these factors and endocrine and inflammatory parameters. This was a prospective controlled study conducted in an academic medical center. The study population consisted of 101 PCOS subjects and 105 control subjects. We divided PCOS subjects into PCOS non-IR (HOMA-IR2.5). Metabolic and anthropometric parameters, total and mitochondrial reactive oxygen species (…

0301 basic medicineMitochondrial ROSendocrine system diseasesmedicine.medical_treatment030204 cardiovascular system & hematologyPathology and Laboratory Medicinemedicine.disease_causeBiochemistryWhite Blood CellsFluorescence MicroscopyEndocrinology0302 clinical medicineAnimal CellsMedicine and Health SciencesLeukocytesInsulinImmune ResponseEnergy-Producing OrganellesMicroscopyMultidisciplinaryQRLight MicroscopyPolycystic ovaryMitochondriaOncologyMyeloperoxidaseHomeostatic model assessmentCytokinesMedicineFemaleCellular TypesCellular Structures and OrganellesInflammation MediatorsResearch ArticlePolycystic Ovary SyndromeAdultmedicine.medical_specialtyAdhesion MoleculesImmune CellsScienceImmunologyBioenergeticsBiologyResearch and Analysis MethodsProinflammatory cytokineYoung Adult03 medical and health sciencesSigns and SymptomsInsulin resistanceDiagnostic MedicineInternal medicineCell AdhesionmedicineHumansPeroxidaseInflammationDiabetic EndocrinologyBlood CellsInsulinBiology and Life SciencesCancers and Neoplasmsnutritional and metabolic diseasesCell BiologyMolecular Developmentmedicine.diseaseHormonesOxidative Stress030104 developmental biologyEndocrinologybiology.proteinInsulin ResistanceReactive Oxygen SpeciesGynecological TumorsOxidative stressDevelopmental Biology
researchProduct

Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer.

2016

Abstract As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly observed in human epithelial cancers, such as non–small cell lung carcinoma (NSCLC), yet definitive demonstration of malignant transformation by deregulated EZH2 remains elusive. Here, we demonstrate the causal role of EZH2 overexpression in NSCLC with new genetically engineered mouse models of lung adenocarcinoma. Deregulated EZH2 silences normal developmental pathways, leading to epigenetic transformation independent of canonical growth factor pathway activation. As such, tumors feature a transcrip…

0301 basic medicineModels MolecularLung Neoplasmsmedicine.medical_treatmentMolecular ConformationGene ExpressionAntineoplastic Agentsmacromolecular substancesBiologymedicine.disease_causeArticleMalignant transformationTargeted therapy03 medical and health sciencesMiceStructure-Activity RelationshipCell Line TumormedicineAnimalsHumansEnhancer of Zeste Homolog 2 ProteinMolecular Targeted TherapyLung cancerPromoter Regions GeneticGene Expression ProfilingEZH2Cancermedicine.diseaseMagnetic Resonance ImagingXenograft Model Antitumor AssaysChromatinrespiratory tract diseasesGene Expression Regulation NeoplasticDisease Models Animal030104 developmental biologyCell Transformation NeoplasticEnhancer Elements GeneticOncologyDrug DesignCancer researchAdenocarcinomaKRASEpigenetic therapyCancer discovery
researchProduct

Role of HSP60/HSP10 in Lung Cancer: Simple Biomarkers or Leading Actors?

2020

Cancers are one of the major challenges faced by modern medicine both because of their impact in terms of the amount of cases and of the ineffectiveness of therapies used today. A concrete support to the fight against them can be found in the analysis and understanding of the molecular mechanisms involving molecular chaperones. In particular, HSP60 and HSP10 seem to play an important role in carcinogenesis, supporting tumours in their proliferation, survival, and metastasis. Efforts must be directed toward finding ways to eliminate or block this “mistaken” chaperone. Therefore, the scientific community must develop therapeutic strategies that consider HSP60 and HSP10 as the possible target …

0301 basic medicineModern medicineDiseaseReview ArticleBioinformaticsmedicine.disease_causeMetastasis03 medical and health sciences0302 clinical medicinemedicineDiagnostic biomarkerLung cancerRC254-282biologybusiness.industrySettore BIO/16 - Anatomia UmanaNeoplasms. Tumors. Oncology. Including cancer and carcinogensHSP60 HSP10 LUNG CANCERmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisChaperone (protein)biology.proteinHSP60businessCarcinogenesis
researchProduct